article thumbnail

Cyfendus Anthrax Vaccine Wins FDA Approval

XTalks

“The approval of Cyfendus vaccine is symbolic of Emergent’s longstanding partnership with the US government and our shared commitment to helping protect public health,” said Dr. Kelly Warfield, Emergent’s senior vice president, science and development, in the company’s press release. What Is Anthrax? How Does Cyfendus Work?

article thumbnail

SnoreStop NasoSpray is Voluntarily Recalled by Green Pharmaceuticals Due to Microbial Contamination

XTalks

Although seldom associated with human disease, it can lead to severe or life-threatening adverse events — such as bacteremia/sepsis, pneumonia, invasive fungal rhinosinusitis, or disseminated fungal infection — in immunocompromised individuals. The NasoSpray was developed to reduce non-apneic snoring. Green Pharmaceuticals Inc.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Symvivo’s Oral COVID-19 Vaccine Enters Clinical Trials

XTalks

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The bacterium then secretes pDNA-protein complexes, triggering an immune response to treat and prevent infection associated with the delivered genes.

article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

is a global pharmaceutical company, working across both developed and emerging markets. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Pfizer Inc.

Sales 98
article thumbnail

Medicago’s Plant-Based COVID-19 Vaccine Enters Human Trials

XTalks

Interim results of the trial show that all participants developed an antibody response after two doses of the COVID-19 adjuvanted vaccine candidate. For example, CpG 1018 promotes development of the Th1 subset of helper T cells by targeting toll-like receptor 9 (TLR9). These are very promising results. Plant-Based Vaccine Technology.

article thumbnail

2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the Life Sciences

XTalks

The pandemic propelled the life science and healthcare sectors onto center stage, and they rose to the occasion against the most unprecedented health challenge in recent times. While COVID-19 has undoubtedly been the biggest story in the life science industry in 2020, it was a busy and positive year in many other areas.